• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

myeloma

  1. Celgene posts upbeat Q1 results on multiple myeloma drug

    Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat prescriptions and longer average duration of use. Revenue continued to be benefited from the company’s key growth driver Revlimid, which was approved...
    • anonymous
    • Thread
    • cancer cancer treatment celgene myeloma
    • Replies: 7
    • Forum: Celgene

  2. Celgene's partnership with Bluebird & Juno

    Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an advantage for all the three companies involved; especially for Bluebird Bio.
    • anonymous
    • Thread
    • american society of hematology bluebird bio cancer cancer treatment celgene juno therapeutics lymphoma myeloma partnership
    • Replies: 3
    • Forum: Celgene
Top Bottom
Back